Is Roche In Trouble With $21 Billion In Sales Nearing Patent Expiry?

Roche Holding's (NASDAQ:RHHBY) key blockbuster drugs - Herceptin and Avastin - will lose their market exclusivity in 2019, while another blockbuster drug, Rituxan, has already lost its exclusivity. These three drugs are important for Roche as they generate $21 billion in annual sales, representin...